AT-A-GLANCE PDF

Back

Not registered yet? Register and SAVE 20% use code "finaldays20" at checkout. DETAILS: ACRM.org/finaldays20

QUESTIONS? --> meetings@ACRM.org

Research Paper

Cancer Rehabilitation

Behavioral Health Sciences

A Decline in Physical Function Is Associated with Cognitive Impairment and Quality of Life in Pancreatic Cancer Patients Undergoing Chemotherapy 4359

Saturday, November 2, 2024

2:45 PM – 3:00 PM

Location: ROOM: Milan REGION: Tower Mezzanine Level >>> DIRECTIONS: Exit Tower elevators on Mezzanine level. Turn left before the skylight. Milan is the third room on the left.

Presenting Author(s)

Amornthep Jankaew (he/him/his)

Dr.
National Cheng Kung University
Tainan, Tainan, Taiwan (Republic of China)

Non-presenting Author(s)

PC

Po See Chen

Dr.
National Cheng Kung University
Tainan, Tainan, Taiwan (Republic of China)

Presenting Author(s)

Cheng-Feng Lin, n/a (she/her/hers)

Professor
National Cheng Kung University
Tainan, Tainan, Taiwan (Republic of China)

Physical Decline Linked to Cognitive Impairment and QoL in Pancreatic Cancer Patients undergoing Chemotherapy

Learning Objectives:

Upon completion, participants will be able to comprehend how chemotherapy induces physical functional status in older individuals with pancreatic cancer, both at the initial stage of chemotherapy doses and throughout a long-term follow-up.
Upon completion, participants will be able to describe the associations between changes in physical function, cognitive abilities, and quality of life in older pancreatic cancer patients undergoing chemotherapy.
Upon completion, participants will be able to design specific intervention and rehabilitation programs with the aim of enhancing physical function, mitigating cognitive impairment, and improving the overall quality of life in older pancreatic cancer patients undergoing chemotherapy.
Upon completion, participants will be able to comprehend how chemotherapy induces physical functional status in older individuals with pancreatic cancer, both at the initial stage of chemotherapy doses and throughout a long-term follow-up.

Disclosure(s):

Amornthep Jankaew: No financial relationships to disclose

Cheng-Feng Lin, n/a: No financial relationships to disclose